A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

NCT01986855 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

468

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Ertugliflozin 5 mg
DRUG: Placebo 5 mg
DRUG: Ertugliflozin 10 mg
DRUG: Placebo 10 mg

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]